S. Kv, C. Is, Yashovardhan A, Suresh Babu B, A. Verma, J. Ds
{"title":"免疫层析和ELISA方法在健康献血者中检测抗hcv抗体的评价:一项初步研究","authors":"S. Kv, C. Is, Yashovardhan A, Suresh Babu B, A. Verma, J. Ds","doi":"10.15380/2277-5706.JCSR.12.018","DOIUrl":null,"url":null,"abstract":"Blood transfusion services are a vital part of modern health care system. With every unit of blood there is 1% chance of transfusion associated problems including transfusion transmitted infectious disease acquisition. Transfusing infected blood to patients in need amounts to a criminal offence. It is mandatory to test every unit of donor blood for antibodies to human immunodeficiency virus (HIV-1 and HIV2), syphilis, hepatitis C, hepatitis B and for malarial parasite. Hepatitis C virus (HCV) is an emerging infection in India and an important pathogen causing liver disease. The prevalence of HCV infection in voluntary or mixed donors has beenobserved to be below 2%. The high risk of chronicity of this blood-borne infection and its association with hepatocellular carcinoma underscores its public health importance. Blood transfusion and unsafe therapeutic interventions by infected needles are two preventable modalities of spread of HCV infection. In modern blood banks, enzyme linked immunosorbent assay (ELISA) method is the recommended and preferred screening method for detecting anti-HCV immunoglobulin G (IgG) antibodies. However, many blood banks in India do not have the facilities to carry out the ELISA test for anti-HCV IgG antibodies and prefer to use “easy to perform”, “user friendly” immunochromatographic rapid screening tests instead. A pilot study was therefore conducted in healthy blood donors to study the performance of immunochromatographic (rapid) device test in the detection of anti-HCV IgG antibodies, considering ELISA method as the ‘gold standard’. The study was carried out on 1002 blood samples collected from apparently healthy voluntary as well as replacement donors over a period of two months. All the samples were tested for anti-HCV IgG antibodies by ELISA method (Hepanostica HCV Ultra; Beijing United Biomedical Co.,LTD,Wales, UK) and immunochromatographic (rapid) device test kit (SD BIOLINE HCV Standard Diagnostics. Inc., Kyongi-do Korea) simultaneously as per the manufacturer’s instructions. Considering ELISA test as gold standard,the sensitivity, specificity, positivepredictive value and negative-predictive value were calculated (Table 1).","PeriodicalId":405143,"journal":{"name":"The Journal of Clinical and Scientific Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2012-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Evaluation of immunochromatographic and ELISA methods in detection of anti-HCV antibodies among healthy blood donors: a pilot study\",\"authors\":\"S. Kv, C. Is, Yashovardhan A, Suresh Babu B, A. Verma, J. Ds\",\"doi\":\"10.15380/2277-5706.JCSR.12.018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Blood transfusion services are a vital part of modern health care system. With every unit of blood there is 1% chance of transfusion associated problems including transfusion transmitted infectious disease acquisition. Transfusing infected blood to patients in need amounts to a criminal offence. It is mandatory to test every unit of donor blood for antibodies to human immunodeficiency virus (HIV-1 and HIV2), syphilis, hepatitis C, hepatitis B and for malarial parasite. Hepatitis C virus (HCV) is an emerging infection in India and an important pathogen causing liver disease. The prevalence of HCV infection in voluntary or mixed donors has beenobserved to be below 2%. The high risk of chronicity of this blood-borne infection and its association with hepatocellular carcinoma underscores its public health importance. Blood transfusion and unsafe therapeutic interventions by infected needles are two preventable modalities of spread of HCV infection. In modern blood banks, enzyme linked immunosorbent assay (ELISA) method is the recommended and preferred screening method for detecting anti-HCV immunoglobulin G (IgG) antibodies. However, many blood banks in India do not have the facilities to carry out the ELISA test for anti-HCV IgG antibodies and prefer to use “easy to perform”, “user friendly” immunochromatographic rapid screening tests instead. A pilot study was therefore conducted in healthy blood donors to study the performance of immunochromatographic (rapid) device test in the detection of anti-HCV IgG antibodies, considering ELISA method as the ‘gold standard’. The study was carried out on 1002 blood samples collected from apparently healthy voluntary as well as replacement donors over a period of two months. All the samples were tested for anti-HCV IgG antibodies by ELISA method (Hepanostica HCV Ultra; Beijing United Biomedical Co.,LTD,Wales, UK) and immunochromatographic (rapid) device test kit (SD BIOLINE HCV Standard Diagnostics. Inc., Kyongi-do Korea) simultaneously as per the manufacturer’s instructions. Considering ELISA test as gold standard,the sensitivity, specificity, positivepredictive value and negative-predictive value were calculated (Table 1).\",\"PeriodicalId\":405143,\"journal\":{\"name\":\"The Journal of Clinical and Scientific Research\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Clinical and Scientific Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15380/2277-5706.JCSR.12.018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical and Scientific Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15380/2277-5706.JCSR.12.018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of immunochromatographic and ELISA methods in detection of anti-HCV antibodies among healthy blood donors: a pilot study
Blood transfusion services are a vital part of modern health care system. With every unit of blood there is 1% chance of transfusion associated problems including transfusion transmitted infectious disease acquisition. Transfusing infected blood to patients in need amounts to a criminal offence. It is mandatory to test every unit of donor blood for antibodies to human immunodeficiency virus (HIV-1 and HIV2), syphilis, hepatitis C, hepatitis B and for malarial parasite. Hepatitis C virus (HCV) is an emerging infection in India and an important pathogen causing liver disease. The prevalence of HCV infection in voluntary or mixed donors has beenobserved to be below 2%. The high risk of chronicity of this blood-borne infection and its association with hepatocellular carcinoma underscores its public health importance. Blood transfusion and unsafe therapeutic interventions by infected needles are two preventable modalities of spread of HCV infection. In modern blood banks, enzyme linked immunosorbent assay (ELISA) method is the recommended and preferred screening method for detecting anti-HCV immunoglobulin G (IgG) antibodies. However, many blood banks in India do not have the facilities to carry out the ELISA test for anti-HCV IgG antibodies and prefer to use “easy to perform”, “user friendly” immunochromatographic rapid screening tests instead. A pilot study was therefore conducted in healthy blood donors to study the performance of immunochromatographic (rapid) device test in the detection of anti-HCV IgG antibodies, considering ELISA method as the ‘gold standard’. The study was carried out on 1002 blood samples collected from apparently healthy voluntary as well as replacement donors over a period of two months. All the samples were tested for anti-HCV IgG antibodies by ELISA method (Hepanostica HCV Ultra; Beijing United Biomedical Co.,LTD,Wales, UK) and immunochromatographic (rapid) device test kit (SD BIOLINE HCV Standard Diagnostics. Inc., Kyongi-do Korea) simultaneously as per the manufacturer’s instructions. Considering ELISA test as gold standard,the sensitivity, specificity, positivepredictive value and negative-predictive value were calculated (Table 1).